SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
633[Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime matuck-12/14/2005
632That is a very good question. I didn't notice anything unexpected in those rIcebrg-12/12/2005
631So why is it down 20%? SamSam Citron-12/12/2005
630Kosan Reports Interim Results of KOS-953 Clinical Trials in Patients With MultipIcebrg-12/12/2005
62917AAG (KS-953) goes to PII with Herceptin: SAN ANTONIO, Texas, Dec. 8 /PRNewswituck-12/8/2005
628Kosan is getting whacked on these interim results for EPO D, which do look kind tuck-12/8/2005
627[Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by 17-AAG] >>tuck-12/4/2005
626[17AAG & DMAG: Dosage a tricky issue] >>Cancer Res. 2005 Dec 1;65(23)tuck-12/4/2005
625Press Release Source: Conforma Therapeutics Corporation Conforma Therapeutics rkrw-11/29/2005
624[Fredericamycin and analogs as novel anticancer agents (really early)] >>tuck-11/26/2005
623[Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Atuck-11/23/2005
622[Role of 17-AAG Hydroquinone in HSP 90 Inhibition; Metabolism of 17-AAG] >&gtuck-11/5/2005
621[RNAi targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17tuck-11/3/2005
620Neutec / HSP90 (nb date of release - I've got a couple of months catching unigel bates-10/31/2005
619No go in HRPC: biz.yahoo.comDewDiligence_on_SI-10/18/2005
618[17AAG versus AML with mutated KIT] >>Leuk Res. 2005 Oct 4; [Epub ahead otuck-10/12/2005
617[Discodermolide: Design, total synthesis, and evaluation of c(13)-c(14) cycloprotuck-10/9/2005
616<i>recent theoretical study has revealed that modular PKSs (such as the erMike McFarland-10/8/2005
615[PK/PD Relationships for 17AAG in Human Ovarian Cancer Xenograft Models] >&gtuck-10/4/2005
614[17AAG -- A new primer regarding Hsp as a pharmacological target] jci.org Fulltuck-10/4/2005
613Maybe the head of the NCI will get together with the Acting FDA commissioner to tom pope-9/29/2005
612Item 8.01. Other Events. As announced on September 12, 2005, Kosan Biosciences Icebrg-9/28/2005
611[17-AAG, ameliorates polyglutamine-mediated motor neuron degeneration] >>tuck-9/13/2005
610Kosan Announces Selection of KOS-2187 as Motilide Clinical Candidate at World Comopgcw-9/12/2005
609Kosan Drops Offering On 'Perceived' Clinical Threat By Karen Pihl-Carey Icebrg-8/28/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News